About BMY Dividend Returns
Bristol-Myers Squibb Company (BMY) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of BMY over the past year?
Bristol-Myers Squibb Company (BMY) delivered a total return of 8.79% over the past year when dividends are reinvested. The price-only return was 4.61%, meaning dividends contributed an additional 4.18 percentage points to total returns.
Q2How much would $10,000 invested in BMY be worth today?
A $10,000 investment in Bristol-Myers Squibb Company one year ago would be worth $10,879 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $10,461. Dividend reinvestment added $418 to the portfolio value.
Q3Does BMY pay dividends?
Yes, Bristol-Myers Squibb Company (BMY) pays dividends. In the last year, BMY paid approximately $2.40 per share in dividends (3.85% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.
Q4Did BMY beat the S&P 500?
No, Bristol-Myers Squibb Company (BMY) underperformed the S&P 500 by 6.66 percentage points over the past year. BMY delivered a total return of 8.79%, compared to the S&P 500's 15.45%. This means a passive S&P 500 index fund outperformed BMY by 6.66pp during this period.
Q5What is BMY's worst drawdown?
Bristol-Myers Squibb Company (BMY) experienced a maximum drawdown of -32.50% over the past year, declining from its peak on 2025-03-10 to its trough on 2025-10-29. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is BMY's long-term total return over 10, 20, or 30 years?
Bristol-Myers Squibb Company (BMY) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is 32.4% (2.8% CAGR) — $10,000 would have grown to $13,244. Over 20 years: 311.8% total return (7.3% CAGR) — $10,000 → $41,177. Over 30 years: 413.7% total return (5.6% CAGR) — $10,000 → $51,371. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was BMY's best and worst year?
Bristol-Myers Squibb Company's best calendar year was 1997 with a total return of 76.7%. Its worst year was 2002 with a total return of -54.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 131.1 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).